Cure My Disease

Don't miss your cure!

 Log in / Sign up

Supercharged t cells aim to block COVID in vulnerable transplant patients

NCT ID NCT05141058

Recruiting now Prevention Sponsor: Children's National Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests whether giving specially grown immune cells (called coronavirus-specific T cells) from a donor can safely prevent COVID-19 infection in people who recently had a stem cell transplant and have weak immune systems. About 24 adults and children will receive one of three doses of these cells. The main goal is to check for side effects, like infusion reactions or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-COV-2 INFECTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's National Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.